Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | CHIEF PEOPLE OFFICER | March 13, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,598 |
Reported balance
After 2026-03-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-13 · Grant · Acquired 3,628 · Balance 29,598 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2: The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026. F3: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.
F2: The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026.
F3: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 20:46 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 3,628 | $4.29 | $15,573.19 |
DisclosureSEC source: 0001790340-26-000044 · wk-form4_1773780394.xml · nonDerivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,598 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 13:14 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 140,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001790340-26-000024 · wk-form4_1770297286.xml · derivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Class A Common Stock · 140,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 13:06 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 2,626 | $4.15 | $10,905.78 |
DisclosureSEC source: 0001790340-26-000010 · wk-form4_1768482368.xml · nonDerivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,970 Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 12:57 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 800 | $6.38 | $5,103.36 |
DisclosureSEC source: 0001790340-25-000123 · wk-form4_1759409848.xml · nonDerivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,344 Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:41 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 11,815 | $1.43 | $16,871.82 |
DisclosureSEC source: 0001790340-25-000115 · wk-form4_1758141678.xml · nonDerivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,544 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 12:52 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 700 | $3.57 | $2,498.65 |
DisclosureSEC source: 0001790340-25-000096 · wk-form4_1751892717.xml · nonDerivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,729 Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:21 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 110,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001790340-25-000030 · wk-form4_1738963291.xml · derivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:14 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 60,500 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024939 · wk-form4_1716495251.xml · derivative · entry 6 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,500 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:14 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 60,500 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001628280-24-024939 · wk-form4_1716495251.xml · derivative · entry 5 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:14 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 105,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024939 · wk-form4_1716495251.xml · derivative · entry 4 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Class A Common Stock · 105,000 shares Expires 2033-02-15 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:14 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 105,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001628280-24-024939 · wk-form4_1716495251.xml · derivative · entry 3 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 105,000 shares Expires 2033-02-15 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:14 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 88,600 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024939 · wk-form4_1716495251.xml · derivative · entry 2 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,600 Underlying: Class A Common Stock · 88,600 shares Expires 2032-10-31 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on October 17, 2023 and then in equal monthly installments over the subsequent three years, subject to Ms. Neufeld's continued employment through each applicable vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:14 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 88,600 | $0.00 Strike: $13.85 | $0.00 |
DisclosureSEC source: 0001628280-24-024939 · wk-form4_1716495251.xml · derivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 88,600 shares Expires 2032-10-31 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on October 17, 2023 and then in equal monthly installments over the subsequent three years, subject to Ms. Neufeld's continued employment through each applicable vesting date. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 13:11 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 3,818 | $2.88 | $10,993.17 |
DisclosureSEC source: 0001790340-24-000036 · wk-form4_1711026670.xml · nonDerivative · entry 2 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,029 Read SEC document |
| March 15, 2024 Filed Mar 21, 2024 13:11 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 6,211 | $1.62 | $10,061.82 |
DisclosureSEC source: 0001790340-24-000036 · wk-form4_1711026670.xml · nonDerivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,211 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:26 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 60,500 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001790340-24-000014 · wk-form4_1707513951.xml · derivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,500 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:16 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 105,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001415889-23-002759 · form4-02172023_040238.xml · derivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Class A Common Stock · 105,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 13:03 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 88,600 | $0.00 Strike: $13.85 | $0.00 |
DisclosureSEC source: 0001415889-22-010973 · form4-11022022_061118.xml · derivative · entry 1 Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,600 Underlying: Class A Common Stock · 88,600 shares Expires 2032-10-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on October 17, 2023 and then in equal monthly installments over the subsequent three years, subject to Ms. Neufeld's continued employment through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.